


Amendments to the Claims:

This listing of Claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claims 1-19 (canceled)

Claim 20 (new): The use of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I



(I)

or a pharmaceutically acceptable salt thereof for the manufacture of pharmaceutical compositions for the treatment of rheumatoid arthritis.

Claim 21 (new): The use according to claim 20 wherein 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I is in the form of a pharmaceutically acceptable acid addition salt.

Claim 22 (new): The use according to claim 21 wherein 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula I is in the form of the monomethanesulfonate salt.

Claim 23 (new): The use according to claim 20 for the treatment of severe rheumatoid arthritis.

Claim 24 (new): The use according to claim 20 for the treatment of DMARD-resistant rheumatoid arthritis.

Claim 25 (new): A method of treating humans suffering from rheumatoid arthritis which comprises administering to said human in need of such a treatment a dose of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide of the formula I or a pharmaceutically acceptable salt thereof.

Claim 26 (new): The method according to claim 25 wherein the compound of formula I is in the form of the monomethanesulfonate salt.

Claim 27 (new): The method according to claim 26 wherein the monomethanesulfonate salt of the compound of formula I is administered at a daily dose corresponding to 100 to 1000 mg of the compound of formula I free base.

Claim 28 (new): The method according to claim 27 wherein the daily dose corresponds to 200 to 800 mg of the compound of formula I free base.

Claim 29 (new): The method for according to claim 25 wherein the administration is once daily for a period exceeding 3 months.

Claim 30 (new): A method of treating mammals suffering from rheumatoid arthritis which comprises administering to said mammal in need of such a treatment a pharmaceutical composition comprising

(a) a dose, effective against rheumatoid arthritis, of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide of the formula I or a pharmaceutically acceptable salt thereof and

(b) a therapeutically effective amount of a second drug selected from the disease modifying arthritis rheumatoid drugs (DMARDs).

Claim 31 (new): The method according to claim 30 wherein the second drug (b) is a non-steroidal anti-inflammatory drug.

Claim 32 (new): The method according to claim 30 wherein the second drug (b) is an anti-inflammatory steroidal drug.

Claim 33 (new): The method according to claim 32 wherein the second drug (b) is prednisone.

Claim 34 (new): Use of a combination which comprises (a) 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide of the formula I or a pharmaceutically acceptable salt thereof and

(b) a second drug selected from the disease modifying arthritis rheumatoid drugs (DMARDs) for the preparation of a medicament for the treatment of rheumatoid arthritis.

Claim 35 (new): A combination which comprises synergistically effective amounts of (a) 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide of the formula I or a pharmaceutically acceptable salt thereof and

(b) a second drug selected from the disease modifying arthritis rheumatoid drugs (DMARDs).

Claim 36 (new): The combination according to claim 35 wherein (b) the second drug is selected from prednisone, cyclosporine and hydroxychloroquine.

Claim 37 (new): The combination according to claim 36 wherein the combination partners are present in synergistically effective amounts.

Claim 38 (new): The combination according to claim 35 wherein the molar ratio (a)/(b) of the combination partners is between 0.1 to 10.

Claim 39 (new): A combination according to claim 38 wherein the molar ratio is between 0.3 to 3.